Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study

Chest

Volumn 151, Issue 6, 2017, Pages 1229-1238

  Marik, Paul E ^a   Khangoora, Vikramjit ^a   Rivera, Racquel ^b   Hooper, Michael H ^a   Catravas, John ^a,c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b SENTARA NORFOLK GENERAL HOSPITAL   (United States)

^c OLD DOMINION UNIVERSITY   (United States)

Author keywords

corticosteroid; hydrocortisone; septic shock; thiamine; vitamin C

Indexed keywords

ASCORBIC ACID; HYDROCORTISONE; HYPERTENSIVE AGENT; THIAMINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; VASOCONSTRICTOR AGENT; VITAMIN B COMPLEX;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EARLY INTERVENTION; ESCHERICHIA COLI; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; SEPSIS RELATED ORGAN FAILURE ASSESSMENT SCORE; SEPTIC SHOCK; SURVIVAL RATE; TREATMENT OUTCOME; ACUTE KIDNEY INJURY; AGED; COMBINATION DRUG THERAPY; HOSPITAL MORTALITY; INTRAVENOUS DRUG ADMINISTRATION; SHOCK, SEPTIC;

ACUTE KIDNEY INJURY; ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ASCORBIC ACID; CONTROLLED BEFORE-AFTER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HOSPITAL MORTALITY; HUMANS; HYDROCORTISONE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEPSIS; SHOCK, SEPTIC; THIAMINE; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS; VITAMIN B COMPLEX;

EID: 85020886166     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.11.036     Document Type: Article

References (93)

1. Adhikari, N.K., Fowler, R.A., Bhagwanjee, S., et al. Critical care and the global burden of critical illness in adults. Lancet 376:9749 (2010), 1339–1346.
2. Kaukonen, K.M., Bailey, M., Suzuki, S., et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 311 (2014), 1308–1316.
3. Gaieski, D.F., Edwards, J.M., Kallan, M.J., et al. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 41 (2013), 1167–1174.
4. Kadri, S.S., Rhee, C., Strich, J.R., et al. Estimating ten-year trends in septic shock incidence and morality in United States Academic Medical Centers using clinical data. Chest 151:2 (2017), 278–285.
5. Marik PE, Linde-Zwirble WT, Bittner EA, et al. Fluid administration in severe sepsis and septic shock, patterns and outcomes: an analysis of a large national database [published online ahead of print January 27, 2017]. Intensive Care Med. http://dx.doi.org/10.1007/s00134-016-4675-y.
6. Silva, E., de Almeida Pedro, M., Beltrami Sogayar, A.C., et al. Brazilian Sepsis Epidemiological Study (BASES study). Crit Care 8:4 (2004), R251–R260.
7. Sales, J.A., David, C.M., Hatum, R., et al., Sepsis Brazil Study. Sepse Brasil: Estudo Epidemiologico da Sepse em Unidades de Terapia Intensiva Brasileiras [An epidemiological study of sepsis in intensive care units]. Rev Bras Ter Int 18 (2006), 9–17.
8. World Health Organization. The top 10 causes of death: the 10 leading causes of death by country income group 2012. WHO fact sheet. http://www.who.int/mediacentre/factsheets/fs310/en/index1.html. Published 2016. Accessed December 15, 2016.
9. Karlsson, S., Ruokonen, E., Varpula, T., et al. Long-term outcome and quality-adjusted life years after severe sepsis. Crit Care Med 37:4 (2009), 1268–1274.
10. Yende, S., Austin, S., Rhodes, A., et al. Long-term quality of life among survivors of severe sepsis: analyses of two international trials. Crit Care Med 44:8 (2016), 1461–1467.
11. Ou, S.M., Chu, H., Chao, P.W., et al. Long-term mortality and major adverse cardiovascular events in sepsis survivors: a nationwide population-based study. Am J Respir Crit Care Med 194:2 (2016), 209–217.
12. Artenstein, A.W., Higgins, T.L., Opal, S.M., Sepsis and scientific revolutions. Crit Care Med 41:12 (2013), 2770–2772.
13. Fisher, B.J., Kraskauskas, D., Martin, E.J., et al. Attenuation of sepsis-induced organ injury in mice by vitamin C. JPEN 38:7 (2014), 825–839.
14. Fisher, B.J., Seropian, I.M., Masanori, Y., et al. Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury. Crit Care Med 39:6 (2011), 1454–1460.
15. Zhou, G., Kamenos, G., Pendem, S., et al. Ascorbate protects against vascular leakage in cecal ligation and puncture-induced septic peritonitis. Am J Physiol Regulatory Integrative Comp Physiol 302:4 (2012), R409–R416.
16. Fowler, A.A., Syed, A.A., Knowlson, S., et al. Phase 1 safety trial of intravenous ascorbic acid in patients with severe sepsis. J Transl Med, 12, 2014, 32.
17. Tanaka, H., Matsuda, T., Miyagantani, Y., et al. Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. Arch Surg 135:3 (2000), 326–331.
18. Long, C.L., Maull, K.L., Krishman, R.S., et al. Ascorbic acid dynamics in the seriously ill and injured. J Surg Res 109:2 (2003), 144–148.
19. de Grooth, H.J., Choo, W.P., Spoelstra-de Man, A.M., et al. Pharmacokinetics of four high-dose regime[n]s of intravenous vitamin C in critically ill patients. [abstract] Intensive Care Med Exp, 4(suppl 1), 2016, A52.
20. Padayatty, S.J., Sun, H., Wang, Y., et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140:7 (2004), 533–537.
21. Nathens, A.B., Neff, M.J., Jurkovich, G.J., et al. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg 236:6 (2002), 814–822.
22. Zabet, M.H., Mohammadi, M., Ramezani, M., et al. Effect of high-dose ascorbic acid on vasopressor requirement in septic shock. J Res Pharm Pract 5:2 (2016), 94–100.
23. Ascorbic acid injection. Torrance Company. http://medlibrary.org/lib/rx/meds/ascorbic-acid-5/. Updated November 18, 2016. Accessed December 15, 2016.
24. Ohno, S., Ohno, Y., Suzuki, N., et al. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res 29:3 (2009), 809–815.
25. Stephenson, C.M., Levin, R.D., Spector, T., et al. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol 72:1 (2013), 139–146.
26. Marik, P.E., Pastores, S.M., Annane, D., et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 36:6 (2008), 1937–1949.
27. Marik, P.E., “Vitamin S” (steroids) and vitamin C for the treatment of severe sepsis and septic shock!. Crit Care Med 44:6 (2016), 1228–1229.
28. Fiore, L.D., Lavori, P.W., Integrating randomized comparative effectiveness research with patient care. N Engl J Med 374:22 (2016), 2152–2158.
29. Wacker, C., Prkno, A., Brunkhorst, F.M., et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 13:5 (2013), 426–435.
30. Schuetz, P., Maurer, P., Punjabi, V., et al. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care, 17(3), 2013, R115.
31. Charles, P.E., Tinel, C., Barbar, S., et al. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and outcome. Crit Care, 13(2), 2016, R38.
32. Reynolds, S.C., Shorr, A.F., Muscedere, J., et al. Longitudinal changes in procalcitonin in a heterogeneous group of critically ill patients. Crit Care Med 40:10 (2012), 2781–2787.
33. Arora, S., Singh, P., Singh, P.M., et al. Procalcitonin levels in survivors and non survivors of sepsis: systematic review and meta-analysis. Shock 43:3 (2015), 212–221.
34. Kutz, A., Briel, M., Christ-Crain, M., et al. Prognostic value of procalcitonin in respiratory tract infections across clinical settings. Crit Care, 19, 2015, 74.
35. Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:6 (1992), 864–874.
36. Mancl, E.E., Muzevich, K.M., Tolerability and safety of enteral nutrition in critically ill patients receiving intravenous vasopressor therapy. JPEN 37:5 (2013), 641–651.
37. Russell, J.A., Walley, K.R., Singer, J., et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:9 (2008), 877–887.
38. Kellum, J.A., Lameire, N., Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care, 17(1), 2013, 204.
39. Knaus, W.A., Draper, E.A., Wagner, D.P., et al. APACHE II: a severity of disease classification system. Crit Care Med 13:10 (1985), 818–828.
40. Zimmerman, J.E., Kramer, A.A., McNair, D.S., et al. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients. Crit Care Med 34:5 (2006), 1297–1310.
41. Vincent, J.L., Moreno, R., Takala, J., et al., Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. The SOFA (Sepsis-Related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 22:7 (1996), 707–710.
42. Marik, P.E., Early management of severe sepsis: current concepts and controversies. Chest 145:6 (2014), 1407–1418.
43. Siemieniuk, R.A., Meade, M.P., Alonso-Coello, P., et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 163:7 (2015), 519–528.
44. Garnacho-Montero, J., Gutierrez-Pizarraya, A., Escoresca-Ortega, A., et al. De-escalation of emperical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 40:1 (2014), 32–40.
45. Marik, P., Bellomo, R., A rational apprach to fluid therapy in sepsis. Br J Anaesth 116:3 (2016), 339–349.
46. Marik, P.E., Fluid responsiveness and the six guiding principles of fluid resuscitation. Crit Care Med 44:10 (2016), 1920–1922.
47. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342:18 (2000), 1301–1308.
48. Girardis, M., Busani, S., Damiani, E., et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. JAMA 316:15 (2016), 1583–1589.
49. Barr, J., Fraser, G.L., Puntillo, K., et al. Clinical practice guidelines for the management of pain, agitation and delirium in adult patients in the intensive care unit. Crit Care Med 41:1 (2013), 263–306.
50. Marik, P.E., Feeding critically ill patients the right “whey”: thinking outside of the box: a personal view. Ann Intensive Care, 5(1), 2015, 51.
51. Marik, P.E., Is early starvation beneficial for the critically ill patient?. Curr Opin Clin Nutr Metab Care 19:2 (2016), 155–160.
52. Marik, P.E., Tight glycemic control in acutely ill patients: low evidence of benefit, high evidence of harm!. Intensive Care Med 42:9 (2016), 1475–1477.
53. Marik, P.E., Stress ulcer prophylaxis de-adoption: what is the barrier?. Crit Care Med 44:10 (2016), 1939–1941.
54. Sprung, C.L., Annane, D., Keh, D., et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:2 (2008), 111–124.
55. Karlsson, S., Heikkinen, M., Pettila, V., et al. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care, 14(6), 2010, R205.
56. Ferreira, F.L., Bota, D.P., Bross, A., et al. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:14 (2001), 1754–1758.
57. de Azevedo, J.R., Torres, O.J., Beraldi, R.A., et al. Prognostic evaluation of severe sepsis and septic shock: procalcitonin clearance vs Δ Sequential Organ Failure Assessment. J Crit Care, 30(1), 2015 219-212.
58. Guan, J., Lin, Z., Lue, H., Dynamic change of procalcitonin, rather than concentration itself, is predictive of survival in septic shock patients when beyond 10 ng/mL. Shock 36:6 (2011), 570–574.
59. Ruiz-Rodriguez, J.C., Caballero, J., Ruiz-Sanmartin, A., et al. Usefulness of procalcitonin clearance as a prognostic biomarker in septic shock: a prospective pilot study. Medicina Intensiva 36:7 (2012), 475–480.
60. D'Agostino, R.B., Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:19 (1998), 2265–2281.
61. Marik, P.E., Pastores, S.M., Kavanaugh, B.P., Selection bias negates conclusions from the CORTICUS study?. N Engl J Med 358 (2008), 2069–2070.
62. Klenner, F.R., The treatment of poliomyelitis and other virus diseases with vitamin C. South Med Surg 111:7 (1949), 209–214.
63. Hench, P.S., Kendall, E.C., Slocumb, C.H., et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and the pituitary adenocorticotrophic hormone on rheumatoid arthritis: preliminary report. Ann Rheum Dis 8:2 (1949), 97–104.
64. Donnino, M.W., Andersen, L.W., Chase, M., et al. Randomized, double-blind, placebo-controlled trial of thiamine as a metabolic resuscitator in septic shock: a pilot study. Crit Care Med 44:2 (2016), 360–367.
65. Gibot, S., Cravoisy, A., Kolopp-Sarda, M.N., et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med 33:4 (2005), 792–796.
66. Gordon, A.C., Mason, A.J., Thirunavukkarasu, N., et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 316:5 (2016), 509–518.
67. Hayes, M.A., Yau, E.H., Hinds, C.J., et al. Symmetrical peripheral gangrene: association with noradrenaline administration. Intensive Care Med 18:7 (1992), 433–436.
68. Dunser, M.W., Wenzel, V., Hasibeder, W.R., Ischemic skin lesions and microcirculatory collapse during vasopressin therapy: a possible role of the microcirculation?. Acta Anaesthesiol Scand 50:5 (2006), 637–638.
69. Stolk, R.F., van der Poll, T., Angus, D.C., et al. Potentially inadvertant immunomodulation: norepinephrine use in sepsis. Am J Respir Crit Care Med 194:5 (2016), 550–558.
70. May, J.M., Role of vitamin C in the function of the vascular endothelium. Antioxid Redox Signal 19:17 (2013), 2068–2083.
71. Wilson, J.X., Evaluation of vitamin C for adjuvant sepsis therapy. Antioxid Redox Signal 19:17 (2013), 2129–2140.
72. Wilson, J.X., Mechanism of action of vitamin C in sepsis: ascorbate modulates redox signaling in endothelium. Biofactors 35:1 (2009), 5–13.
73. Han, M., Pendem, S., Teh, S.L., et al. Ascorbate protects endothelial barrier function during septic insult: role of protein phosphatase type 2A. Free Radic Biol Med 48:1 (2010), 128–135.
74. Dillon, P.F., Root-Bernstein, R.S., Lieder, C.M., Antioxidant-independent ascorbate enhancement of catecholamine-induced contractions of vascular smooth muscle. Am J Physiol Heart Circ Physiol 286:6 (2004), H2353–H2360.
75. Marik, P.E., Critical illness related corticosteroid insufficiency. Chest 135:1 (2009), 181–193.
76. Kalden, J.R., Prolonged skin allograft survival in vitamin C-deficient guinea-pigs: preliminary communication. Eur Surg Res 4:2 (1972), 114–119.
77. Kim, S.R., Ascorbic acid reduces HMGB1 secretion in lipopolysaccharide-activated RAW 264.7 cells and improves survival rate in septic mice by activation of Nrf2/HO-1 signals. Biochem Pharmacol 95:4 (2015), 279–289.
78. Manning, J., Mitchell, B., Appadurai, D.A., et al. Vitamin C promotes maturation of T-cells. Antioxid Redox Signal 19:17 (2013), 2054–2067.
79. Fogarty, A., Scrivener, S.L., Antoniak, M., et al. Corticosteroid sparing effects of vitamin C and magnesium in asthma: a randomised trial. Respir Med 100:1 (2006), 174–179.
80. Bodwell, J.E., Holbrook, N.J., Munck, A., Sulfhydryl-modifying reagents reversibly inhibit binding of glucocorticoid-receptor complexes to DNA-cellulose. Biochemistry 23:7 (1984), 1392–1398.
81. Okamoto, K., Tanaka, H., Ogawa, H., et al. Redox-dependent regulation of nuclear import of the glucocorticoid receptor. J Biol Chem 274:15 (1999), 10363–10371.
82. Okamoto, K., Tanaka, H., Makino, Y., et al. Restoration of the glucocorticoid receptor function by the phosphodiester compound of vitamins C and E, EPC-K1 (l-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl hydrogen phosphate] potassium salt), via a redox-dependent mechanism. Biochem Pharmacol 56:1 (1998), 79–86.
83. Burzle, M., Hediger, M.A., Functional and physiological role of vitamin C transporters. Curr Top Membr 70 (2012), 357–375.
84. Seno, T., Inoue, N., Matsui, K., et al. Functional expression of sodium-dependent vitamin C transporter 2 in human endothelial cells. J Vasc Res 41:4 (2004), 345–351.
85. Fujita, I., Hirano, J., Itoh, N., et al. Dexamethasone induces sodium-dependant vitamin C transporter in a mouse osteoblastic cell line MC3T3-E1. Br J Nutr 86:2 (2001), 145–149.
86. Barabutis N, Khangoora V, Marik PE, et al. Hydrocortisone and ascorbic acid synergistically protect against LPS-induced pulmonary endothelial barrier dysfunction. Chest. In press.
87. Keh, D., Trips, E., Marx, G., et al., SepNet-Critical Care Trials Group. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS Randomized Clinical Trial. JAMA 316:17 (2016), 1775–1785.
88. Minneci, P.C., Deans, K.J., Eichacker, P.Q., et al. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 15:4 (2009), 308–318.
89. Massey, L.K., Ascorbate increases human oxaluria and kidney stone risk. J Nutr 135:7 (2005), 1673–1677.
90. Wandzilak, T.R., Effect of high dose vitamin C on urinary oxalate levels. J Urol 151:4 (1994), 834–837.
91. Hoppe, B., Beck, B.B., Milliner, D., The primary hyperoxalurias. Kidney Int 75:12 (2009), 1264–1271.
92. Sidhu, H., Gupta, R., Thind, S.K., et al. Oxalate metabolism in thiamine-deficient rats. Ann Nutr Metab 31:6 (1987), 354–361.
93. Ortiz-Alvarado, O., Muyaoka, R., Kriedberg, C., et al. Pyridoxine and dietary counseling for the management of idiopathic hyperoxaluria in stone-forming patients. Urology 77:5 (2011), 1054–1058.